Cellbyte, a Munich-based AI-native platform helping pharmaceutical companies accelerate drug launches, has raised $2.75 million in seed funding. The round was led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital and Springboard Health Angels.
The funding will support Cellbyte’s international expansion, triple its headcount and automate more drug launch workflows. The company has already reached six figures in ARR within weeks of launching and secured contracts with major pharmaceutical firms including Bayer.
Felix Steinbrenner, Co-CEO and Co-Founder at Cellbyte said: “The success of a drug’s entire lifecycle is decided in its launch sequence. Insights derived from gigabytes of accurate, up-to-date information are needed to make the best decisions for a launch.
“The traction Cellbyte has secured with some of the world’s biggest pharmaceutical companies since its launch shows the industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost-effective processes.”
Cellbyte’s platform enables Market Access teams to analyse millions of data points in real time across clinical, pricing, HTA and regulatory data. It replaces legacy databases that only surface limited data, allowing users to generate insights and documents in minutes rather than months.
Daniel Moreira, Co-CEO and Co-Founder at Cellbyte said: “Based on my years in Life Science Consulting, I’ve seen countless innovations transforming clinical development. Yet in Pricing and Market Access, decisions still too often rely on manual work and anecdotal evidence even though information is so abundant. Now, generative AI is changing that, and we’re proud to be driving this shift.”
William McQuillan, Partner at Frontline Ventures said: “Cellbyte is tackling one of pharma’s biggest bottlenecks with an AI-driven strategy. Felix, Samuel and Daniel have set their sights globally from day one, and we’re proud to support them as they expand into the US, accelerating patient access to new treatments.”
